N Biotechnol. 2012 Jun 15;29(5):511-4. doi: 10.1016/j.nbt.2012.05.003.
In affinity proteomics, specific protein-binding molecules (a.k.a. binders), principally antibodies, are applied as reagents in proteome analysis. In recent years, advances in binder technologies have created the potential for an unprecedented view on protein expression and distribution patterns in plasma, cells and tissues and increasingly on protein function. Particular strengths of affinity proteomics methods include detecting proteins in their natural environments of cell or tissue, high sensitivity and selectivity for detection of low abundance proteins and exploiting binding actions such as functional interference in living cells. To maximise the use and impact of affinity reagents, it will be essential to create comprehensive, standardised binder collections. With this in mind, the EU FP7 programme AFFINOMICS (http://www.affinomics.org), together with the preceding EU programmes ProteomeBinders and AffinityProteome, aims to extend affinity proteomics research by generating a large-scale resource of validated protein-binding molecules for characterisation of the human proteome. Activity is directed at producing binders to about 1000 protein targets, primarily in signal transduction and cancer, by establishing a high throughput, coordinated production pipeline. An important aspect of AFFINOMICS is the development of highly efficient recombinant selection methods, based on phage, cell and ribosome display, capable of producing high quality binders at greater throughput and lower cost than hitherto. The programme also involves development of innovative and sensitive technologies for specific detection of target proteins and their interactions, and deployment of binders in proteomics studies of clinical relevance. The need for such binder generation programmes is now recognised internationally, with parallel initiatives in the USA for cancer (NCI) and transcription factors (NIH) and within the Human Proteome Organisation (HUPO). The papers in this volume of New Biotechnology are all contributed by participants at the 5th ESF Workshop on Affinity Proteomics organised by the AFFINOMICS consortium and held in Alpbach, Austria, in March 2011.
在亲和蛋白质组学中，特定的蛋白质结合分子（也称为结合剂），主要是抗体，被用作蛋白质组分析中的试剂。近年来，结合剂技术的进步为在血浆、细胞和组织中观察蛋白质表达和分布模式，以及越来越多地观察蛋白质功能，提供了前所未有的可能性。亲和蛋白质组学方法的特别优势包括在细胞或组织的自然环境中检测蛋白质，对低丰度蛋白质的检测具有高灵敏度和选择性，并利用结合作用，如在活细胞中进行功能干扰。为了最大限度地利用亲和试剂并发挥其作用，创建全面、标准化的结合剂库将是至关重要的。考虑到这一点，欧盟第七框架计划 AFFINOMICS（http://www.affinomics.org）与之前的欧盟计划 ProteomeBinders 和 AffinityProteome 一起，旨在通过生成大规模经过验证的蛋白质结合分子资源来扩展亲和蛋白质组学研究，以对人类蛋白质组进行特征描述。该计划的活动旨在通过建立高通量、协调的生产管道，针对约 1000 个蛋白质靶标（主要是信号转导和癌症）生产结合剂。AFFINOMICS 的一个重要方面是开发基于噬菌体、细胞和核糖体展示的高效重组选择方法，这些方法能够以比以往更高的通量和更低的成本生产高质量的结合剂。该计划还涉及开发用于特定靶蛋白及其相互作用的灵敏检测的创新技术，并将结合剂部署到具有临床相关性的蛋白质组学研究中。这种结合剂生成计划的需求现在在国际上得到了认可，美国在癌症（NCI）和转录因子（NIH）以及人类蛋白质组组织（HUPO）方面也有类似的计划。本期《新生物技术》中的所有论文均由 AFFINOMICS 联盟组织的第五届 ESF 亲和蛋白质组学研讨会的参与者提交，该研讨会于 2011 年 3 月在奥地利阿尔卑巴赫举行。
